# DESCRIPTION

## FIELD OF THE INVENTION

- define isolated peptide for use as a medicament

## BACKGROUND OF THE INVENTION

- introduce natural killer cells
- describe role of NK cells in immune responses
- discuss HCMV infection and its effects
- summarize expansion and adaptation of NK cells
- describe characteristics of adaptive NK cells
- discuss HLA-E and its role in NK cell activation
- summarize prior art on peptide recognition and NK cell activation
- highlight limitations of prior art
- emphasize need for new means of harnessing NKG2C+ cells

## SUMMARY OF THE INVENTION

- introduce technical problem
- state problem to be solved
- summarize invention
- describe isolated peptide
- describe isolated peptide for use as medicament
- describe preferred embodiment of isolated peptide
- explain surprising finding
- describe activation of NKG2C+NK cells
- describe receptor specific activation
- describe application in treatment of diseases
- describe specific activating effect on NKG2C+NK cells
- describe use as medicament to expand and/or activate NKG2C+NK cells
- describe treatment of cancer and HCMV infections
- introduce peptides of the present invention
- motivate combination with pro-inflammatory cytokines
- describe check point inhibitors
- application of check point inhibitors
- motivate combination with activator of CD2
- describe administration of peptide with IFN-alpha
- describe administration by vector
- describe in vitro method for cultivating NKG2C+ NK cells
- describe characteristics of isolated population of NKG2C+ NK cells
- describe use of isolated population as medicament
- describe genetically modified virus encoding peptide
- describe use of genetically modified virus as medicament
- summarize preferred embodiments

## DETAILED DESCRIPTION OF THE INVENTION

- incorporate cited documents by reference
- introduce isolated peptide for use as medicament
- define amino acid sequences of preferred polypeptides
- describe embodiments of polypeptides with varying lengths
- define functionally analogous sequences
- describe modifications to polypeptides
- introduce natural killer cells and their function
- describe CD94/NKG2 family of receptors
- explain NKG2 receptors and their function
- describe non-classical MHC glycoproteins class I
- introduce HLA-G and its isoforms
- describe HLA-E and its function
- explain role of non-classical MHC class I molecules in immune system
- describe medical conditions associated with pathogenic cells
- define expansion and/or activation of NKG2C+ NK cells
- describe medical conditions and cancers associated with pathogenic cells expressing HLA-E and a peptide
- motivate use of peptides as a medicament to treat medical conditions
- describe role of UL-40 protein in HCMV immune evasion
- explain how peptides can be used to inhibit reactivation of HCMV infections
- describe application of invention to patients with active or latent HCMV infection
- relate to treatment of cancer associated with elevated expression of HLA-G
- describe methods for determining HLA-E and HLA-G expression levels
- define "treatment of a tumor" in the context of the invention
- classify cancers into subcategories
- list examples of leukemias, sarcomas, melanomas, and carcinomas
- describe additional cancers that can be treated with the invention
- define "tumor" in the context of the invention
- describe administration of peptide in combination with an adjuvant
- explain role of adjuvants in enhancing immune response
- list examples of immunological adjuvants
- define pro-inflammatory cytokines and their role in immune response
- list examples of cytokines that can be used to stimulate immune response
- describe use of checkpoint inhibitors in combination with peptide
- explain role of immune checkpoint molecules in immune system
- define checkpoint modulators and their role in immune response
- define checkpoint modulators
- list co-inhibitory checkpoint molecules
- describe LILRB1
- describe A2AR
- describe B7-H3
- describe B7-H4
- describe BTLA
- describe CTLA-4
- describe IDO
- describe anti-cancer therapies
- describe gene therapy
- introduce genetically modified cells
- describe polypeptide expression
- discuss cell migration
- describe local administration
- introduce biocompatible matrix
- describe peptide entrapment
- discuss pharmaceutical composition
- define nucleic acid
- define polypeptide
- describe modifications for in vivo half-life
- discuss peptide additions or deletions
- describe carriers for administration
- list administration routes
- describe pharmaceutically acceptable carriers
- discuss composition formulation
- define therapeutically effective amount
- describe dosage ranges
- discuss inducible expression
- define treatment and prophylaxis
- describe combined administration

### EXAMPLES

- describe human subjects
- describe cell lines and cells
- amplify and sequence UL40-encoded peptide sequences
- stabilize HLA E surface
- stimulate NK cells in vitro
- perform cytotoxicity assays
- culture NK cells in vitro
- perform flow cytometry
- analyze expression of HCMV UL40
- describe experimental methods
- generate HCMV mutant viral strains
- describe mutagenesis process
- outline construction of BAC TB40R-Cre
- detail mathematical model of NK cell proliferation
- introduce Gett/Hodgkin model
- describe model modifications
- validate methylation profiles using NGS
- outline PCR amplicon design and sequencing
- analyze gene expression using NGS
- describe statistical analysis methods
- outline method for determining HLA-E surface expression
- describe method for determining HLA-G expression
- summarize patient characteristics

### Summary of the Results

- propose HCMV peptides contribute to shape adaptive NKG2C+ NK-cell populations

### Example 1: Sequence Variations in HCMV UL40-Encoded Peptides Control the Activation of Adaptive NKG2C+ NK Cells

- analyze heterogeneity of NKG2C+NK cells in healthy HCMV+ individuals
- identify sequence variations in HCMV UL40-encoded peptides
- demonstrate differential recognition of peptides by adaptive NKG2C+NK cells
- show peptide recognition controls activation of adaptive NKG2C+NK cells

### Example 2: Co-Stimulatory Signals are Required to Elicit Polyfunctionality of Adaptive NKG2C+NK Cells Upon Engagement with Sub-Optimal Peptides

- examine role of co-stimulatory signals in peptide recognition

### Example 3: Adaptive NKG2C+NK Cells Differentially Recognize HCMV-Encoded Peptides During Infection

- demonstrate differential recognition of HCMV-encoded peptides during infection

### Example 4: Peptide Recognition Controls Relative Accumulation of NKG2C+NK Cells from HCMVâˆ’ Individuals in the Presence of Pro-Inflammatory Signals

- examine role of peptide recognition in NKG2C+NK-cell proliferation
- demonstrate synergistic effect of peptide recognition and co-stimulation
- model NKG2C+NK-cell proliferation and accumulation dynamics

### Example 5: Peptide Recognition and Pro-Inflammatory Cytokines Co-Operate in Guiding the Differentiation of Adaptive NKG2C+ NK Cells

- examine role of peptide recognition and pro-inflammatory cytokines in adaptive NK-cell differentiation
- demonstrate transcriptional modulation of adaptive NK-cell markers
- show functional up-regulation of activation and exhaustion markers
- analyze global transcriptional imprinting of adaptive NK cells

### Discussion of Examples 1-5

- discuss HCMV-induced adaptive NKG2C+NK cells
- motivate UL40-encoded peptides as immune evasion strategy
- describe NKG2C-mediated responses to UL40 polymorphisms
- propose immune pressure underlying UL40 sequence heterogeneity
- discuss HCMV UL40 peptides resembling self-peptides
- describe activation of adaptive NKG2C+NK cells by viral mimics
- analyze CD94/NKG2 heterodimers and peptide recognition
- discuss compensatory mechanisms in NKG2C-deficient individuals
- describe generation of adaptive Ly49H+ NK cells
- conclude on specific innate recognition of HCMV-infected cells

